Indivior PLC

INDV

GB00BN4HT335

Indivior PLC is a pharmaceutical company. The Company is engaged in developing medicines to treat substance use disorders (SUD), serious mental illnesses, and opioid overdose. It has a pipeline of product candidates designed to address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder, and co-morbidities, including schizophrenia. Its core products include SUBLOCADE (buprenorphine extended release) monthly injection; SUBOXONE Film (buprenorphine and naloxone sublingual film); SUBOXONE Tablet (buprenorphine and naloxone sublingual tablets), and SUBUTEX Tablet (buprenorphine sublingual tablets). Its products for the treatment of opioid disorders (OUD) are OPVEE (nalmefene) nasal spray for opioid overdose reversal, and PERSERIS (risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults in the United States. Its portfolio of products is available in 37 countries.

Employees

1,000

Sector

Pharmaceuticals

Calendar

30/10/2024 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

9.805USD

Average target price

23.34USD

Spread / Average Target

+138.02%

Consensus

Profit revisions

Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar

Market Closed - London S.E. Other stock markets 16:35:26 13/09/2024 BST			5-day change	1st Jan Change
746.00 ^GBX	+2.68%		-6.05%	-37.05%

09-05	Transcript : Indivior PLC Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-05-2024 10:45 AM
09-04	Indivior reports "disappointing" results for study with Aelis Farma	AN

Transcript : Indivior PLC Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-05-2024 10:45 AM	09-05
Indivior reports "disappointing" results for study with Aelis Farma	09-04	AN
Aelis Farma: share price falls after clinical failure	09-04	CF
Aelis Farma: cautious on the downside, phase 2b study failure	09-04	CF
Indivior to Forgo Option to License Aelis Farma's Cannabis Use Disorder Drug	09-04	MT
Indivior PLC Provides Update on Aelis Farma's Clinical Phase 2B Study Results with AEF0117 in Participants with Moderate to Severe Cannabis Use Disorder	09-04	CI
Addex Therapeutics Ltd and Indivior PLC Selects Clinical Candidates from Gabab Positive Allosteric Modulator Research Collaboration	08-27	CI
Indivior, Addex to Advance Clinical Candidates Following Collaboration	08-27	MT
Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research Collaboration	08-27	DJ
Indivior Says BARDA Makes 1st Order of Opioid Overdose Reversal Nasal Spray	08-26	MT
UBS raises Hargreaves Lansdown; DB cuts JD	08-12	AN
European shares rise amid turbulent week for stocks	08-09	RE
Tranche Update on Indivior PLC's Equity Buyback Plan announced on November 17, 2023.	08-06	CI
Indivior Completes $100 Million Share Buyback Program	08-06	MT
Indivior PLC's Equity Buyback announced on November 17, 2023 has closed with 5,944,547 shares, representing 4.35% for $99.99 million.	08-05	CI
European companies cut jobs as economy sputters	08-05	RE
Indivior Secures $86 Million Settlement Deal for Alleged Involvement in Opioid Addiction Crisis in US	07-28	MT
Indivior to Pay $86 Million in Multistate Opioid Settlement, New York Attorney General Says	07-26	MT
Indivior reaches $86 million opioid settlement with US states	07-26	RE
Indivior shares soar on $100 million buyback, opioid addiction drug sales rise	07-25	RE
Indivior Shares Rise After Q2 Adjusted Earnings, Revenue Rise	07-25	MT
Transcript : Indivior PLC, Q2 2024 Earnings Call, Jul 25, 2024	07-25
Indivior PLC Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	07-25	CI
Earnings woe sends European stocks lower	07-25	AN
Astra ups outlook; Unilever and Lloyds back view	07-25	AN

Indivior PLC

Equities